sarilumab
Tocilizumab
Tocilizumab Tocilizumab, a monoclonal anti-IL-6-receptor blocking antibody, has been proposed as a therapeutic agent to mitigate hyperinflammation associated with COVID-19. Tocilizumab is FDA-approved for various rheumatologic conditions as well as cytokine release syndrome associated with CAR-T cell therapy. Why are are interleukin-6 (IL-6) receptor antagonists considered for treatment? Some patients with COVID-19 develop a hyperinflammatory […]
Related lists
Hospital Lists